Pharmacogenomics is a rapidly developing sector of human genetics research with arguably the highest potential for immediate benefit. There is a considerable body of evidence demonstrating that variability in drug-treatment response can be explained in part by genetic variation. Subsequently, much research has ensued and is ongoing to identify genetic variants associated with drug-response phenotypes. To reap the full benefits of the data we collect we must give careful consideration to the study population under investigation, the phenotype being examined and the statistical methodology used in data analysis. Here, we discuss principles of study design and optimizing statistical methods for pharmacogenomic studies when the outcome of interest is a continuous measure. We review traditional hypothesis testing procedures, as well as novel approaches that may be capable of accounting for more variance in a quantitative pharmacogenomic trait. We give examples of studies that have employed the analytical methodologies discussed here, as well as resources for acquiring software to run the analyses.